PDC*Line Pharma
Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a Belgian biotech company that develops an innovative class of active immunotherapies for cancers, based on an allogeneic antigen presenting cell line (PDC*line). PDC*line is a new potent and scalable therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells. PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors. The technology can be applied for any type of cancer. Based on a first-in-human phase I study in melanoma, PDC*line Pharma focuses on the development of a candidate for lung cancer (PDC*lung) and neoantigens (PDC*Neo). The company raised more than 15M€ in equity and loans and regroup a team of 15 peoples with a seasonal management team lead by Eric Halioua (President & CEO).
